Trial Profile
A Phase III, Randomized, Double-Blind, Multicenter, Comparative Study to Determine the Efficacy and Safety of Cefepime-Tazobactam vs. Meropenem Followed by Optional Oral Therapy in the Treatment of Complicated Urinary Tract Infection or Acute Pyelonephritis in Adults
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 19 Jul 2023
Price :
$35
*
At a glance
- Drugs Cefepime/tazobactam (Primary) ; Ciprofloxacin; Meropenem
- Indications Pyelonephritis; Urinary tract infections
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Wockhardt
- 14 Jul 2023 Planned End Date changed from 25 Apr 2025 to 1 Feb 2026.
- 14 Jul 2023 Planned primary completion date changed from 25 Mar 2025 to 1 Jan 2026.
- 14 Jul 2023 Planned initiation date changed from 25 Jan 2024 to 1 Jan 2024.